Response to treatment with yttrium 90-DOTA-lanreotide of a patient with metastatic gastrinoma.

Abstract

1,4,7,10-tetraazacyclododecane-N,N',N",N'''-tetraacetic acid (DOTA)-lanreotide is a universal somatostatin (SST) receptor subtype ligand that binds to a large variety of human tumors. We report the case of a patient with metastatic gastrinoma who was treated with 90Y-DOTA-lanreotide. Before treatment, dosimetry with 111In-DOTA-lanreotide (150 MBq, 10 nmol) indicated a dose of 5.8 mGy/MBq for the recurrent abdominal gastrinoma, and a mean dose of approximately 1.0 mGy/MBq for liver metastases (i.e., 56 and approximately 10 mGy/MBq for 90Y-DOTA-lanreotide, respectively). After four infusions of 90Y-DOTA-lanreotide (each 1 GBq, approximately 30 nmol) over a 6-mo period, the 111In-DOTA-lanreotide scintigraphy of the liver had returned to a nearly normal condition and a remarkably decreased uptake by the recurrent gastrinoma was calculated (approximately 5 mGy/MBq for 90Y-DOTA-lanreotide). The imaging results were well-correlated with a 25% regression of the liver metastases as indicated by CT. Blood, urine and whole-body clearances of 111In-DOTA-lanreotide and 90Y-DOTA-lanreotide were very similar. The DOTA-lanreotide promises to be useful for functional tumor diagnosis (111In-DOTA-lanreotide) and receptor-mediated tumor radiotherapy (90Y-DOTA-lanreotide).

• Authors: M Leimer, A Kurtaran, P Smith-Jones, M Raderer, E Havlik, P Angelberger, F Vorbeck, B Niederle, C Herold, I Virgolini
• Journal: Journal of nuclear medicine : official publication, Society of Nuclear Medicine (J Nucl Med) Vol. 39 Issue 12 Pg. 2090-4 (Dec 1998) ISSN: 0161-5505 [Print] United States
• PMID: 9867148 (Publication Type: Case Reports, Journal Article)

Chemical References

• Heterocyclic Compounds
• Peptides, Cyclic
• Radiopharmaceuticals
• Receptors, Somatostatin
• indium 111-DOTA-lanreotide
• yttrium 90-DOTA-lanreotide

Topics

• Gastrinoma (diagnostic imaging, pathology, radiotherapy, secondary)
• Heterocyclic Compounds (pharmacokinetics, therapeutic use)
• Humans
• Liver Neoplasms (diagnostic imaging, radiotherapy, secondary)
• Lymph Node Excision
• Male
• Metabolic Clearance Rate
• Middle Aged
• Pancreatic Neoplasms (pathology, radiotherapy, surgery)
• Peptides, Cyclic (pharmacokinetics, therapeutic use)
• Radiopharmaceuticals (pharmacokinetics, therapeutic use)
• Receptors, Somatostatin (agonists)
• Recurrence
• Tomography, Emission-Computed, Single-Photon
• Tomography, X-Ray Computed